KalVista Pharmaceuticals, Inc.
KALV
$11.85
$0.100.85%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.43M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.43M | -- | -- | -- | -- |
| Cost of Revenue | 60.85M | 71.71M | 81.07M | 91.00M | 93.47M |
| Gross Profit | -59.42M | -71.71M | -81.07M | -91.00M | -93.47M |
| SG&A Expenses | 143.37M | 116.29M | 100.36M | 80.64M | 62.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 204.22M | 188.00M | 181.42M | 171.63M | 155.57M |
| Operating Income | -202.79M | -188.00M | -181.42M | -171.63M | -155.57M |
| Income Before Tax | -197.55M | -180.05M | -171.62M | -156.39M | -141.77M |
| Income Tax Expenses | 5.55M | 3.39M | 4.25M | -- | -- |
| Earnings from Continuing Operations | -203.10 | -183.45 | -175.87 | -156.39 | -141.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -203.10M | -183.45M | -175.87M | -156.39M | -141.77M |
| EBIT | -202.79M | -188.00M | -181.42M | -171.63M | -155.57M |
| EBITDA | -201.82M | -187.06M | -180.52M | -170.76M | -154.72M |
| EPS Basic | -3.93 | -3.69 | -3.73 | -3.64 | -3.54 |
| Normalized Basic EPS | -2.42 | -2.28 | -2.30 | -2.29 | -2.23 |
| EPS Diluted | -3.93 | -3.69 | -3.73 | -3.64 | -3.54 |
| Normalized Diluted EPS | -2.42 | -2.28 | -2.30 | -2.29 | -2.23 |
| Average Basic Shares Outstanding | 205.88M | 198.61M | 189.16M | 171.24M | 159.11M |
| Average Diluted Shares Outstanding | 205.88M | 198.61M | 189.16M | 171.24M | 159.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |